

# Digital Biomarkers Tailored Around Parkinson's Patients

## Better Data. Faster Results.

Digital biomarkers produce better clinical trial data that enable more confident decisions and speed up timelines. As the leader in digital biomarker development, Koneksa is at the forefront of this evolution. We employ novel and existing measures and algorithms alongside advanced digital health technology for more frequent, objective data. Our cutting-edge algorithms and innovative digital measures can be deployed rapidly and at scale, accelerating and enhancing drug development programs. This comprehensive approach follows regulatory guidance and is uniquely positioned to empower Parkinson's disease research sponsors to overcome expensive and time-consuming operational challenges in their studies.

Koneksa makes it easier to obtain accurate, reliable data with configurable capabilities and ready-to-use devices for patients, as well as the training materials and support necessary for quick and seamless study startup.



## Solutions Specific to Your Study

Koneksa partners with you early on in your clinical development programs and works collaboratively throughout the study process to optimize study design, data collection and management, analysis, and evaluation of results. Our device-agnostic platform and measurement solutions can be configured to your Parkinson's disease study requirements, generating exciting real-world insights from the best possible data, earlier and faster than with traditional measures.

## Testing Patients Where They Live

Traditional clinical trials focused on Parkinson's disease face omnipresent data-skewing factors due to the point-in-time limitations of in-clinic evaluation, subjective measurements, and the nature of the disorder. By moving data collection into the patient's home, a fuller picture of the condition is realized through more regular evaluation, and since data are collected by devices, human bias is removed. Additionally, reducing anxiety-inducing travel eases the process for Parkinson's patients. Koneksa's digital remote collection methods meet Parkinson's patients where they live, doing away with the burdens that stand in the way of collecting better, more objective data.

## Rethink Your Research

Leading with science, Koneksa is helping shape a new era of Parkinson's disease research, collecting better data faster and enabling quicker "go/no-go" decisions by putting the patient at the center of continuous remote data collection. Informed by more than five years of direct collaboration with biopharma Parkinson's disease sponsors across multiple stages of research, several validation studies, and global clinical and regulatory engagements, our work provides targeted benefits that offset the challenges inherent in traditional CNS trials.

## Why Koneksa is the right partner for Parkinson's disease research:



Seamless remote data collection leveraging trusted digital health technology — lowers patient burden, increases convenience, and improves compliance



More robust proprietary algorithms — aligned with innovative capabilities to produce better data in less time



A dynamic, device-agnostic platform — crucial for research in a disease with a variety of symptoms, questions, and investigational therapies being studied



An array of wearables — enables measurement of multiple Parkinson's disease symptoms for a better understanding of drug effects



A higher standard in quality data — offers a much higher frequency of collection than MDS-UPDRS and other standard measures



More objective remote data collection — removes subjective clinician observation that can introduce human error and skew results



Evidence that guides future success in Parkinson's research — thorough data sets that show which protocols produced the most compliance

**Get better study data and faster results.**  
Partner with Koneksa on your next Parkinson's disease trial.

[hello@koneksahealth.com](mailto:hello@koneksahealth.com)